Plus Therapeutics presented data from the FORESEE study of its CNSide platform for the diagnosis and management of LM. The data were presented in a podium presentation at the 2024 Society for NeuroOncology, SNO/American Society for Clinical Oncology, ASCO, CNS Metastases Conference August 8-10, 2024 in Denver, Colorado. Key results from the FORESEE trial: The trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target; CNSide demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. cytology (29%) in patients with LM; CNSide identified actionable mutations in the CSF, such as HER2 amplification, influencing 24% of therapeutic selection decisions; CNSide exhibited high specificity, with no tumor cells detected in patients without LM
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
- Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
- Plus Therapeutics presents interim ReSPECT-LM phase 1 data
- Is PSTV a Buy, Before Earnings?
- Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024